暴降70%!泰格医药闪崩,CRO失去最后避风港

市场资讯
Yesterday

来源:E药资本界CXO最后的堡垒被击碎,意味着新一轮大战,全面开始。AI浪潮袭来,CRO行业正从“人力密集型”向“技术驱动型”演进。行业结构性调整的阵痛,无人能幸免。药明、康龙化成之后,轮到CRO血统最纯正的大哥——泰格医药了。作为中国CXO行业“最后的堡垒”,CRO一哥终于顶不住了——2024年迎来了业绩创纪录式的大跌:根据预告,其上市以来年营收首次出现下滑;归母净利润预计同比骤降72%-81%...

Source Link

Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.

Most Discussed

  1. 1
     
     
     
     
  2. 2
     
     
     
     
  3. 3
     
     
     
     
  4. 4
     
     
     
     
  5. 5
     
     
     
     
  6. 6
     
     
     
     
  7. 7
     
     
     
     
  8. 8
     
     
     
     
  9. 9
     
     
     
     
  10. 10